Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Go back to Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.11 +0.11 (1.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.00 | 52 Week High | $9.23 | |||
| Open | $9.89 | 52 Week Low | $1.16 | |||
| Day High | $10.15 | P/E | N/A | |||
| Day Low | $9.76 | EPS | $-0.30 | |||
| Volume | 11,145,262 | |||||
